Faculty

Back to Index
Hossein Jadvar, MD, PhD
Associate Professor of Radiology
Director of Radiology Research
Radiology
CSC 102 Health Sciences Campus Los Angeles
+1 323 442 1107

Overview

Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI
Associate Professor of Radiology
Associate Professor of Biomedical Engineering
University of Southern California, Los Angeles, CA USA
Past President, American College of Nuclear Medicine (ACNM)
Past President, Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Dr. Jadvar is a tenured associate professor of radiology (Keck School of Medicine) and biomedical engineering (Viterbi School of Engineering) at the University of Southern California (USC) with hospital appointments at the USC Keck Medical Center, USC Norris Comprehensive Cancer Center, and the LAC+USC Medical Center. He also served as a visiting associate in bioengineering at the California Institute of Technology in Pasadena, Calif. Dedicated to lifelong learning, Dr. Jadvar received his BS in chemical engineering from Iowa State University in Ames, Iowa, in 1982, followed by a MS in biomedical engineering from the University of Wisconsin in Madison, Wis., in 1984, and a MS in computer engineering, as well as a PhD in bioengineering, from the University of Michigan in Ann Arbor, Mich., in 1986 and 1988, respectively. He then attended the University of Chicago Pritzker School of Medicine in Chicago, Ill., for his MD degree (1993). He received his MPH degree from Harvard University in Cambridge, Mass., in 2005 and an Executive MBA from the University of Southern California in Los Angeles, Calif., in 2007. He was a clinical fellow in positron emission tomography with the Harvard Medical School Joint Program in Nuclear Medicine, in Boston, Mass., during 1998-99; a diagnostic radiology and nuclear medicine resident at Stanford University, in Stanford, Calif., during 1994-98; and an intern in internal medicine at the University of California San Francisco, Calif., during 1993-94. He has also completed a number of executive educational certificate programs at Harvard Medical School in Boston, Mass., the University of Cambridge in the UK, the University of Oxford in the UK, and the Wharton School of Business at the University of Pennsylvania in Philadelphia, Penn. Dr. Jadvar is on the editorial boards of the Journal of Nuclear Medicine, the European Journal of Nuclear Medicine and Molecular Imaging, Molecular Imaging and Biology, Radiology (Consultant to the Editor), American Journal of Roengenology (Assistant Editor), and Clinical Nuclear Medicine (Deputy Editor), and many others. He is the past president of the American College of Nuclear Medicine (ACNM) and the past recipient of the SNMMI Mark Tetalman Young Investigator Award, the Western Regional SNMMI Distinguished Scientist Award, the Academy of Radiology Research Distinguished Investigator Award, and the inaugural Prof. Ajit Padhy Oration Memorial Award from the World Association of Radiopharmaceuticals and Molecular Therapy (WARMTH), and the USC Excellence in Mentoring Award. He is a National Institutes of Health (NIH) funded investigator and serves on multiple NIH review panels (with one term as a chartered member), Department of Defense, and the Imaging Technology and Informatics Peer Review Panel of the Cancer Prevention and Research Institute of Texas (CPRIT). He is a fellow of ACNM, SNMMI, and the USC Center for Excellence in Research. He is an established nuclear medicine expert for the International Atomic Energy Agency (IAEA). He has written more than 120 journal articles, has published 4 books, 28 book chapters, 9 patents and has given more than 250 invited speaker presentations and visiting professorships at numerous national and international venues. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particular current interest in prostate cancer. (http://www-hsc.usc.edu/~jadvar)

Awards

World Association of Radiopharmacutical and Molecular Therapy (WARMTH): Prof. Ajit Padhy Memorial Oration Award, 2016

Journal of Nuclear Medicine (Supplement on Prostate Cancer): Invited Guest Editor, 2016

Society of Nuclear Medicine and Molecular Imaging (SNMMI): Fellow, 2016

Academy of Radiology Research: Distinguished Investigator Award, 2014

Best Doctors in America

Pasadena Magazine: San Gabriel Valley Top Doctors, 2010-2013

35th Annual Western Regional Society of Nuclear Medicine: Distinguished Scientist Award, 2010

PET Clinics and Theranostics (Prostate Cancer): Invited Guest Editor, 2009

USC Center for Excellence in Research: Inaugural Faculty Fellow, 2007-2010

IEEE-Engineering in Medicine and Biology Society: Senior Member, 2006

American College of Nuclear Medicine (ACNM): Fellow, 2003

Society of Nuclear Medicine: Marc Tetalman Young Investigator Award, 2000

American College of Nuclear Physicians (ACNP): Resident Research Award, 1998

Radiological Society of North America: Roentgen Resident/Fellow Research Award, 1997

NIH: NIH Resident Research Award, 1994

Publications

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol. 2017 Aug; 209(2):277-288. View in: PubMed

Highlights of articles published in annals of nuclear medicine 2016. Eur J Nucl Med Mol Imaging. 2017 Jul 28. View in: PubMed

Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy. World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. View in: PubMed

ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. J Nucl Med. 2017 Jul; 58(7):1174-1176. View in: PubMed

Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer. Clin Transl Imaging. 2017 Jun; 5(3):199-208. View in: PubMed

Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque? Radiology. Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque? Radiology. 2017 Apr; 283(1):1-3. View in: PubMed

Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Res. 2017 02; 37(2):475-479. View in: PubMed

SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. J Nucl Med. 2017 Jan; 58(1):11-12. View in: PubMed

Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants? Clin Imaging. Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants? Clin Imaging. 2016 Nov - Dec; 40(6):1237-1245. View in: PubMed

Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 Nov; 46(6):502-506. View in: PubMed

PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):25S-29S. View in: PubMed

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):19S-24S. View in: PubMed

Radiotheranostics in Prostate Cancer: Introduction and Overview. J Nucl Med. 2016 Oct; 57(Suppl 3):1S-2S. View in: PubMed

Pathways to the Future of Nuclear Medicine Task Force: Phase 1 Report. J Nucl Med. 2016 Sep; 57(9):17N-9N. View in: PubMed

Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016 Jul; 34(7):470-85. View in: PubMed

SNMMI Leadership Update: Challenges, Opportunities, and Accomplishments. J Nucl Med. 2016 Jun; 57(6):18N. View in: PubMed

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol (NY). 2016 May; 41(5):889-98. View in: PubMed

SNMMI Leadership Update: Pathways to the Future of Nuclear Medicine. J Nucl Med. 2016 Apr; 57(4):15N. View in: PubMed

Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomark Cancer. 2016; 8(Suppl 2):35-8. View in: PubMed

SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. J Nucl Med. 2015 Nov; 56(11):20N. View in: PubMed

Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis. Tomography. 2015 Sep; 1(1):18-22. View in: PubMed

PSMA PET in Prostate Cancer. J Nucl Med. 2015 Aug; 56(8):1131-2. View in: PubMed

Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clin Nucl Med. 2015 Aug; 40(8):e426-8. View in: PubMed

Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy. J Nucl Med. 2015 Jul; 56(7):1119-29. View in: PubMed

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. View in: PubMed

Prognostic Utility of PET in Prostate Cancer. PET Clin. 2015 Apr; 10(2):255-63. View in: PubMed

American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. J Nucl Med. 2015 Apr; 56(4):642-5. View in: PubMed

Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. View in: PubMed

Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. Semin Nucl Med. 2015 Jan; 45(1):58-65. View in: PubMed

Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. Asia Ocean J Nucl Med Biol. 2015; 3(2):72-6. View in: PubMed

SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance. J Nucl Med. 2014 May; 55(5):699-700. View in: PubMed

The SNMMI and EANM practice guideline for tele-nuclear medicine 2. 0. J Nucl Med Technol. 2014 Mar; 42(1):15-9. View in: PubMed

Competitive advantage of PET/MRI. Eur J Radiol. 2014 Jan; 83(1):84-94. View in: PubMed

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. View in: PubMed

Targeted a-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. View in: PubMed

Molecular imaging of prostate cancer with PET. J Nucl Med. 2013 Oct; 54(10):1685-8. View in: PubMed

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. View in: PubMed

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1:S5-10. View in: PubMed

FDG-PET/MRI fusion demonstrating cricoarytenoid muscle hypermetabolism due to contralateral true vocal cord paralysis. Rev Esp Med Nucl Imagen Mol. 2012 Nov; 31(6):362-3. View in: PubMed

FDG-PET/MRI fusion demonstrating cricoarytenoid muscle hypermetabolism due to contralateral true vocal cord paralysis. Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec; 31(6):362-3. View in: PubMed

The SNMMI practice guideline for therapy of thyroid disease with 131I 3. 0. J Nucl Med. 2012 Oct; 53(10):1633-51. View in: PubMed

[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. Mol Imaging. 2012 Sep-Oct; 11(5):426-32. View in: PubMed

Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012 Aug; 199(2):278-91. View in: PubMed

PET/CT in prostate cancer: non-choline radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2012 Aug; 56(4):367-74. View in: PubMed

Multimodality imaging in biochemical recurrence of prostate cancer: Utility of (18)F-NaF PET/CT in early detection of metastasis. Rev Esp Med Nucl Imagen Mol. 2012 Jul; 31(4):231-2. View in: PubMed

Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis. Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. View in: PubMed

Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012 Jul; 42(4):247-54. View in: PubMed

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. View in: PubMed

Preservation of retinotopic map in retinal degeneration. Exp Eye Res. 2012 May; 98:88-96. View in: PubMed

Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics. Can Choline PET Tackle the Challenge of Imaging Prostate Cancer? Theranostics. 2012; 2(3):331-2. View in: PubMed

FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. View in: PubMed

Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease. Clin Nucl Med. 2011 Sep; 36(9):754-6. View in: PubMed

ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Clin Nucl Med. 2011 Aug; 36(8):e72-80. View in: PubMed

Modeling and percept of transcorneal electrical stimulation in humans. IEEE Trans Biomed Eng. 2011 Jul; 58(7):1932-9. View in: PubMed

Prostate cancer. Methods Mol Biol. 2011; 727:265-90. View in: PubMed

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011 Jan; 52(1):81-9. View in: PubMed

Evolving cardiac conduction phenotypes in developing zebrafish larvae: implications to drug sensitivity. Zebrafish. 2010 Dec; 7(4):325-31. View in: PubMed

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. View in: PubMed

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 1; 70(12):1359-70. View in: PubMed

Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2010 Mar; 51(3):498-9; author reply 499-500. View in: PubMed

18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009 Nov; 50(11):1820-7. View in: PubMed

Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 2009 Jun; 6(6):317-23. View in: PubMed

FDG PET in Prostate Cancer. PET Clin. 2009 Apr 01; 4(2):155-61. View in: PubMed

Preface. PET Clin. 2009 Apr; 4(2):ix. View in: PubMed

FDG PET in Prostate Cancer. PET Clin. 2009 Apr 1; 4(2):155-61. View in: PubMed

Role of Imaging in Prostate Cancer. PET Clin. 2009 Apr 1; 4(2):135-8. View in: PubMed

Role of Imaging in Prostate Cancer. PET Clin. 2009 Apr 01; 4(2):135-8. View in: PubMed

Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. 2009 Mar-Apr; 8(2):56-64. View in: PubMed

Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med. 2009 Jan-Apr; 12(1):26-9. View in: PubMed

[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008 Nov; 22(9):787-93. View in: PubMed

Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging. 2008 May-Jun; 7(3):147-52. View in: PubMed

A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol. 2008 Mar; 65(3):449-61. View in: PubMed

[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008 Feb; 13(1):42-7. View in: PubMed

PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007 Sep; 37(5):316-31. View in: PubMed

[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr. 2007 Mar-Apr; 31(2):223-8. View in: PubMed

Adenocarcinoma in an Indiana pouch on PET-CT. Clin Nucl Med. 2007 Jan; 32(1):57-8. View in: PubMed

Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT. Clin Nucl Med. 2006 Oct; 31(10):646-7. View in: PubMed

2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006 May-Jun; 8(3):193-200. View in: PubMed

FDG PET-CT demonstration of Sjogren's sialoadenitis. Clin Nucl Med. 2005 Oct; 30(10):698-9. View in: PubMed

Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005 Apr-Jun; 4(2):91-7. View in: PubMed

PET in pediatric diseases. Radiol Clin North Am. 2005 Jan; 43(1):135-52. View in: PubMed

Musculoskeletal system. Semin Nucl Med. 2004 Oct; 34(4):254-61. View in: PubMed

The reproductive tract. Semin Nucl Med. 2004 Oct; 34(4):262-73. View in: PubMed

Electrocardiographic characterization of embryonic zebrafish. Conf Proc IEEE Eng Med Biol Soc. 2004; 5:3615-7. View in: PubMed

Fusion positron emission tomography-computed tomography demonstration of epidural metastases. Clin Nucl Med. 2004 Jan; 29(1):39-40. View in: PubMed

Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003 Dec; 60(6):395-400. View in: PubMed

FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. View in: PubMed

Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003 Mar; 58(3):215-21. View in: PubMed

Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol. 2002 Dec; 31(12):690-4. View in: PubMed

Procedure guideline for telenuclear medicine 1. 0. J Nucl Med. 2002 Oct; 43(10):1410-3. View in: PubMed

Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002 Sep; 224(3):783-7. View in: PubMed

Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results. Radiographics. 2002 May-Jun; 22(3):477-90. View in: PubMed

Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging. 2001 May-Jun; 26(3):254-9. View in: PubMed

Non-visualization of sentinel lymph node in patients with breast cancer. Nucl Med Commun. 2001 Jan; 22(1):25-32. View in: PubMed

Comparison of fluorine-18 deoxyglucose and O-15 water PET in temporal lobe epilepsy. Acta Neurol Belg. 2000 Dec; 100(4):214-20. View in: PubMed

Medical imaging in microgravity. Aviat Space Environ Med. 2000 Jun; 71(6):640-6. View in: PubMed

The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med. 2000 Jan; 25(1):48-51. View in: PubMed

Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med. 1999 Dec; 24(12):965-7. View in: PubMed

Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide. Clin Positron Imaging. 1999 Nov; 2(6):318. View in: PubMed

SPECT and PET in the evaluation of coronary artery disease. Radiographics. 1999 Jul-Aug; 19(4):915-26. View in: PubMed

Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. Clin Positron Imaging. 1999 May; 2(3):153-158. View in: PubMed

Annular pancreas in adults: imaging features in seven patients. Abdom Imaging. 1999 Mar-Apr; 24(2):174-7. View in: PubMed

Role of FDG PET in the Evaluation of Rare Tumors. Clin Positron Imaging. 1998 Sep; 1(4):239. View in: PubMed

Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 1998 Jun; 19(6):547-54. View in: PubMed

Effect of radionuclide renograms on treatment of patients with spinal cord injuries. AJR Am J Roentgenol. 1997 Oct; 169(4):1045-7. View in: PubMed

False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med. 1997 Sep; 38(9):1382-3. View in: PubMed

Still the great mimicker: abdominal tuberculosis. AJR Am J Roentgenol. 1997 Jun; 168(6):1455-60. View in: PubMed

Computer analysis of the electrocardiogram during esophageal pacing cardiac stress. IEEE Trans Biomed Eng. 1991 Nov; 38(11):1089-99. View in: PubMed

A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms. Med Phys. 1990 May-Jun; 17(3):380-90. View in: PubMed

Utility of a stimulus artifact suppressor for transesophageal pacing. Am J Cardiol. 1990 Feb 1; 65(5):393-4. View in: PubMed

Utility of a stimulus artifact suppressor for transesophageal pacing. Am J Cardiol. 1990 Feb 01; 65(5):393-4. View in: PubMed

A system for simultaneous esophageal atrial pacing and ventricular recording in computer analysis of posterior ischemia. J Electrocardiol. 1989; 22 Suppl:248-52. View in: PubMed

The pill electrode. New technology as an adjunct to nursing assessment of patient arrhythmias. Prog Cardiovasc Nurs. 1989 Jan-Mar; 4(1):10-7. View in: PubMed

Computer processing of the electrocardiogram during transesophageal atrial pacing-induced stress. J Electrocardiol. 1987 Oct; 20 Suppl:106-7. View in: PubMed

Lead configurations in esophageal electrocardiography. Med Instrum. 1987 Jun; 21(3):158-65. View in: PubMed

Powered bySC CTSI